Federal Register Notice: FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will meet 6/10, from 8:30 a.m. to 5 p.m. at the Holiday Inn, Bethesda, MD. The committee will discuss a supplemental new drug application for Humatroper (somatropin recombinant deoxyribonucleic acid (rDNA) origin) for injection), Eli Lilly and Co., for the proposed indication of treatment of nongrowth hormone deficiency short stature. Contact Dornette Spell-LeSane, 301-827-7001. To view this notice, click here.
